|
|
Article: Opexa Therapeutics Reports Third Quarter 2009 Financial Results and Corporate Update.(Financial report)
- Article from:
- Business Wire
- Article date:
- November 4, 2009
CopyrightCOPYRIGHT 2009 Business Wire. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
THE WOODLANDS, Texas -- Opexa Therapeutics, Inc. (NASDAQ: OPXA), a company developing a novel T-cell therapy for multiple sclerosis (MS), today reported financial results for the quarter ended September 30, 2009, and provided details on further developments.
Recent highlights include:
* 3rd quarter net income of $2.2 million as a consequence of the gain on the sale of the Company's stem cell technology;
* Closing of sale of early stage adult stem cell technology to Novartis and achievement of first technology transfer milestone; and
* Receipt of approximately $1.2 million in additional cash from warrant exercises before and after ...